Company Encyclopedia
View More
name
Veracyte
VCYT.US
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services.
1.945 T
VCYT.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking24/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE2.49%C
    • Profit Margin6.12%B
    • Gross Margin71.27%A
  • Growth ScoreB
    • Revenue YoY16.41%B
    • Net Profit YoY427.11%A
    • Total Assets YoY7.28%B
    • Net Assets YoY6.94%B
  • Cash ScoreB
    • Cash Flow Margin1633.21%B
    • OCF YoY16.41%B
  • Operating ScoreC
    • Turnover0.37C
  • Debt ScoreA
    • Gearing Ratio8.05%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Officer Febbo Surrenders 2,955 Of Veracyte Inc [VCYT]

    Officer Febbo Phillip of Veracyte Inc surrendered 2,955 shares back to the company to cover option exercise costs and tax liabilities, as disclosed in a Form 4 filed with the SEC on December 4, 2025. The transaction was valued at $136,403, with shares priced at $46.16. Febbo's ending holdings are 89,486 shares directly.

    Reuters·
    US
    VCYT
    -3.46%
    Reuters·
    US
    VCYT
    -3.46%

    VP Wygant Surrenders 1,325 Of Veracyte Inc [VCYT]

    Veracyte Inc's Vice President, Jonathan Wygant, surrendered 1,325 shares at $46.16 each, valued at $61,162, to cover option exercise costs and/or tax liabilities. His remaining direct holdings are 37,420 shares.

    Reuters·
    US
    VCYT
    -3.46%
    Reuters·
    US
    VCYT
    -3.46%

    VP McGuire Sells 1,422 ($67.3K) Of Veracyte Inc [VCYT]

    Veracyte Inc's Vice President, Annie McGuire, disclosed a Form 4 filing with the SEC, indicating a surrender of 3,052 shares and a planned sale of 1,422 shares, valued at $67,261, under a prearranged trading plan. The transaction was executed to cover option exercise costs and tax liabilities, leaving McGuire with 78,499 direct holdings.

    Reuters·
    US
    VCYT
    -3.46%
    Reuters·
    US
    VCYT
    -3.46%

    CEO Stapley Sells 7,668 ($361.1K) Of Veracyte Inc [VCYT]

    Veracyte Inc's CEO, Marc Stapley, disclosed a stock transaction involving the sale of 7,668 shares for $361,075, as per a Form 4 filed with the SEC. The transaction was part of a prearranged trading plan (10b5-1). Additionally, 7,914 shares were surrendered to cover option exercise costs and tax liabilities. Stapley's direct holdings now total 318,603 shares.

    Reuters·
    US
    VCYT
    -3.46%
    Reuters·
    US
    VCYT
    -3.46%

    Officer Leite Sells 1,278 ($60.7K) Of Veracyte Inc [VCYT]

    Officer John Leite of Veracyte Inc filed a Form 4 with the SEC, disclosing a surrender of 2,900 shares and a planned sale of 1,278 shares under a 10b5-1 trading plan. The transactions were executed to cover option exercise costs and tax liabilities, with ending holdings of 82,113 shares.

    Reuters·
    US
    VCYT
    -3.46%
    Reuters·
    US
    VCYT
    -3.46%
    © 2025 Longbridge｜Disclaimer